Table 5.

Univariate and multivariate analyses to identify predictors for time to hepatotoxicity related to erlotinib administration

Characteristics	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Male	0.876 (0.530–1.448)	1.045 (0.579–1.886)
Age ≥ 65	1.314 (0.797–2.169)	1.265 (0.764–2.095)
BSA ≥ 1.6a	0.795 (0.483–1.309)	0.771 (0.431–1.377)
Liver metastasis	1.897 (1.100–3.275)**	2.052 (1.179–3.572)*
CYP3A4 inducer	2.017 (0.918–4.433)	2.318 (1.029–5.221)*

For multivariate analysis, factors with p < 0.1 in the univariate analysis were included in addition to sex, age and BSA

BSA body surface are

^aThere was 1 missing data for BSA

^*P < 0.05, ^**P < 0.01